Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 3Tumor-Agnostic 1Thoracic 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Lung Neoplasms 1

Interventions

Carboplatin 351pembrolizumab 323Pemetrexed 248Cisplatin 220Paclitaxel 148Nivolumab 138durvalumab 134osimertinib 112atezolizumab 110Docetaxel 110Specimen Handling 91Radiotherapy 87Drug Therapy 85Magnetic Resonance Spectroscopy 77Etoposide 77Radiosurgery 72Gemcitabine 71Ipilimumab 54130-nm albumin-bound paclitaxel 54Bevacizumab 52cemiplimab 47tislelizumab 45Blood Specimen Collection 40Cetuximab 35Taxes 34Platinum 33Injections 33Biopsy 33Standard of Care 31Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Artificial Intelligence × Thoracic × 1 year × Clear all
NCT07458425 2026-04-06

The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk

University of Illinois at Chicago

Phase NA Recruiting
400 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡